Improving response to progestin treatment of low-grade endometrial cancer.

Eva BaxterDonal J BrennanJessica N McAlpineJennifer J MuellerFrédéric AmantMignon D J M van GentDavid G HuntsmanRobert L ColemanShannon N WestinMelinda S YatesCamilla KrakstadMichael A QuinnMonika JandaAndreas Obermair

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)

Molecular markers can identify cases which may be candidates for progestin treatment. More work is needed to validate these biomarkers and potentially identify new ones. Predictive biomarkers are anticipated to inform future research into progestin treatment of low-grade endometrial cancer and ultimately improve patient outcomes.

Keyphrases

low grade
endometrial cancer
high grade
combination therapy
replacement therapy
smoking cessation